High-dose Inhaled NO Therapy for the pREvenvention of NP After Cardiac Surgery Under CPB
Key facts
- Who runs it
- Tomsk National Research Medical Center of the Russian Academy of Sciences
- Where
- Russia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 160 people enrolled
- Started
- 20 Feb 2024
- Ended
- 1 Oct 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Sham treatment
- 200-ppm NO
- Record updated
- 24 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (16)Hide the full registry criteria
Who can take part
- Cardiac surgery with CPB at current hospitalization
- Age > 18 years
- Signed informed consent
Who cannot take part
- Emergency surgery
- Acute coronary syndrome 30 days before surgery
- Surgery for active infective endocarditis requiring antibiotic therapy
- Taking antibacterial drugs for 14 days preceding surgery
- Potentially dialysis-dependent stage 2 and higher acute kidney injury (according to KDIGO) in the early postoperative period (the criteria for potentially dialysis-dependent acute kidney injury will include patients with stage 2 acute kidney injury and: oliguria against the background of normo-hypervolemia and resistance to loop diuretics and/ or oliguria against the background of conducting infusion therapy due to hypovolemia and resistance to loop diuretics)
- Patient's participation in another clinical trial at the time of screening or within the previous 3 months
- Concomitant pulmonary disease with the need for respiratory support before surgery
- Diagnosed infectious process of another localization (surgical site infection (SSI), acute and chronic urinary tract infection (active), catheter-related bloodstream infection, peritonitis, etc.)
- Other complications of the postoperative period (pneumothorax requiring pleural drainage, perioperative myocardial infarction accompanied by pulmonary edema, shock of any etiology during the current hospitalization)
- History of malignancy or other irreversible diseases/conditions with a 6- month mortality rate >50%
- Continued mechanical ventilation
- Delirium
- Presence of tracheostomy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary aim of this single-center, prospective, randomized, controlled, study is to test the hypothesis that inhalation of NO 200 ppm prevents the development of nosocomial pneumonia in patients at risk after cardiac surgery under CPB. The study is interventional. Examination and treatment of patients is carried out in accordance with the approved standards of medical care for the relevant diseases. During the study, no experimental or unregistered (not approved for use) medical or diagnostic procedures in the territory of the Russian Federation will be carried out. The study includes patients admitted to the Cardiac Surgery Department of Cardiology Research Institute of Tomsk National Research Medical Center for elective surgery with CPB.
The 2 groups in the trial
- Control groupExisting treatment, for comparison
Oxygen-air mixture without NO after extubation within 5 days after surgery 2 times a day for 30 min
Treatment: Sham treatment
- 200 ppmTreatment being tested
NO will be supplemented at 200-ppm concentration after extubation within 5 days after surgery 2 times a day for 30 min
Treatment: 200-ppm NO
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- High-dose Inhaled NO Therapy for the pREvention of nosoCOmial Pneumonia After Cardiac Surgery Under caRDiopulmonary Bypass
- Record updated
- 24 June 2026